| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Fondaparinux
MessageThis is the Anti-Xa level assay for patients taking fondaparinux (Arixtra). Performed in the Hematology Laboratory x5475 Sample MUST be drawn to minimum fill line on tube
Test Code
ARIX
Alias/See Also
Fondaparinux
CPT Codes
85520
Preferred Specimen
plasma
Minimum Volume
2.7 mL sodium citrate tube. Sample MUST be drawn to minimum fill line on tube or the sample will be rejected as QNS.
Instructions
Specimen MUST be collected 3 hours after administration of Arixtra and should not be collected from an indwelling line containing any kind of heparin.
Transport Container
Light blue top (sodium citrate), 2.7mL draw tube
Transport Temperature
Room Temperature
Specimen Stability
Refrigerator Stability: 4 hours
Plasma is stable for 6 months frozen at -70 degrees C.
Plasma is stable for 6 months frozen at -70 degrees C.
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Grossly hemolyzed, QNS, clotted
Methodology
Chromogenic
Setup Schedule
As needed. Mon-Friday, 8:30-4 pm
Limitations
This assay cannot differentiate between different types of heparin if multiple types are present in the specimen. The cumulative Anti-Xa activity will be measured.
Results show no interference with hemoglobin up to 300 mg/dL, triglycerides up to 800 mg/dL, and bilirubin up to 20mg/dL.
Results show no interference with hemoglobin up to 300 mg/dL, triglycerides up to 800 mg/dL, and bilirubin up to 20mg/dL.
Reference Range
Anti-Xa levels are not routinely required and the target range is not well established.
VTE Prophylaxis: The mean peak steady state concentration 3 hours post dose was 0.39 - 0.50 ug/mL.
Therapeutic anticoagulation: When dosing by weight with either 5 mg (weight <50 kg), 7.5 mg (weight 50 – 100 kg), or 10 mg (weight > 100 kg), the mean peak steady state concentration 3 hours post dose was 1.20 - 1.26 ug/mL.
Reference: Garcia DA, Baglin TP, Weitz JI, Samama MM. Chest. 2012 Feb; 141(2 Suppl): e24S–e43S.
VTE Prophylaxis: The mean peak steady state concentration 3 hours post dose was 0.39 - 0.50 ug/mL.
Therapeutic anticoagulation: When dosing by weight with either 5 mg (weight <50 kg), 7.5 mg (weight 50 – 100 kg), or 10 mg (weight > 100 kg), the mean peak steady state concentration 3 hours post dose was 1.20 - 1.26 ug/mL.
Reference: Garcia DA, Baglin TP, Weitz JI, Samama MM. Chest. 2012 Feb; 141(2 Suppl): e24S–e43S.
Clinical Significance
Test the Anti-Xa level of patient's taking Arixtra (Fondaparinux) therapy.
